RAN Biotechnologies has entered into a distributorship agreement with Fluigent for distribution of RAN Biotechnologies products in Europe.
“We are very excited to be distributing the products of RAN Biotechnologies,” said Dr. Jérémie Weber, CTO and co-founder of Fluigent. “Their chemicals and solutions are the state-of-the-art for droplet microfluidics. We believe the combination of RAN Biotechnologies reagents and our microfluidic instruments will lead to a very powerful platform for droplet microfluidic applications.”
Droplet microfluidics is an alternative technology for Lab-on-a-chip systems, where manipulation of discrete micro-droplets is performed. Such a technology is compatible with many chemicals and biologicals and allows the programmation of various digital fluidic operations. These valuable advantages have the potential to enhance biomedical research and secure a rapidly growing market share in diagnostics and therapeutics.
“Our expertise in synthetic and surface chemistry in general and in surfactants in particular, allows us to develop advanced materials for microfluidics”, said Dr. Roger Nassar, founder and President of RAN Biotechnologies. Dr. Nassar added, “Partnering with Fluigent is a major step in our exposure efforts in Europe after winning the Young Entrepreneurs initiative (YEi’13) award, which is organized by the French Embassy in the United States and the French Innovation Network (Retis). It will help us to reach a wider microfluidic market and allow us to be part of important new technologies by advancing lab-on-a-chip applications.”
RAN Biotechnologies’ fluorosurfactants and microfluidic surface coatings stabilize water-in-oil emulsions for droplet microfluidics and can encapsulate biologicals, such as DNA, RNA, cells and proteins, permitting their study and interrogation. High-throughput single cell screening, DNA amplification and chemical reactions are some of the manipulations performed inside these unique droplets.